Checkpoint Inhibitor denied as non-formulary by Cigna?

Cigna's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Checkpoint Inhibitors as Non-Formulary

Cigna's non-formulary denial for a checkpoint inhibitor means the specific agent prescribed is either not included on the patient's plan formulary or is placed on a coverage tier that requires additional justification before benefits apply. Because checkpoint inhibitors are high-cost oncology agents, they are commonly managed through specialty-tier or closed-formulary structures where coverage depends on meeting specific criteria even before formulary placement is considered. In some cases, a non-formulary denial reflects a situation where a different checkpoint inhibitor in the same class is listed as the formulary-preferred agent.

## Why This Denial Is Appealable

Non-formulary denials are adverse benefit determinations with full internal and external appeal rights under ACA §2719 and ERISA §503. In the oncology context, formulary-exception requests carry particular weight because checkpoint inhibitors for a given tumor type are not always interchangeable — different agents have different FDA-approved indications, different biomarker requirements, and different clinical profiles. The external-review window is typically 4 months from the final internal denial, with an expedited pathway for urgent oncology situations. Cancer treatment routinely qualifies for expedited review.

The core legal argument is a formulary exception: that the non-formulary agent is medically necessary because the formulary alternative is clinically inappropriate, not approved for this patient's specific tumor type and indication, or otherwise not a suitable substitute.

## The Appeal Process

1. Identify which checkpoint inhibitor, if any, is listed as the formulary-preferred alternative and obtain its FDA-approved prescribing information. 2. Have the treating oncologist document why the formulary alternative is not appropriate — focusing on differences in FDA-approved indication, required biomarker eligibility, or clinical evidence base for this specific tumor type. 3. Submit a formulary exception request (often a parallel, faster track) alongside a formal written appeal. 4. Request a peer-to-peer review with Cigna's oncology medical director. 5. Escalate to external review if the internal process is exhausted.

## Documentation to Gather

• FDA label comparison: The indication sections of both the prescribed agent and any formulary alternative, showing differences in approved use.
• Pathology, biomarker, and staging records: Confirming the specific tumor type and profile driving the agent selection.
• Oncologist's formulary-exception letter: Explaining clinically why the non-formulary agent is required and why the listed alternative does not adequately serve this patient's documented needs.
• Prior authorization history: Any prior approvals for oncology agents, demonstrating treatment continuity if applicable.

## Criteria-Mapping Structure

Obtain Cigna's formulary-exception criteria. Build a point-by-point response addressing each criterion. Where the exception rests on clinical non-interchangeability with the formulary agent, provide a side-by-side comparison of the FDA-approved indications and relevant biomarker requirements, drawn directly from the prescribing labels. Clear, structured documentation addressed to each criterion gives reviewers and IRO clinicians the fastest path to a coverage decision in the patient's favor.